Clinical trials: Diabetes Type I
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 (insulin degludec, IDeg) formulations in subjects with type 1 diabetes.
- Trial name
- NCT01076634
- Testing
- insulin degludec
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT)
The purpose of this study is to evaluate the impact of the Abbott Sensor Based Glucose Monitoring System on hypoglycaemia compared to Self Monitoring Blood Glucose (SMBG) testing using a randomised controlled study design in…
- Trial name
- IMPACT (NCT02232698)
- Testing
- Sensor Based Glucose Monitoring System, Standard Blood Glucose Monitoring
- Where
- 23 sites in Austria, Germany and 3 more
- Volunteers
- 328 people
- Sponsor
- Abbott Diabetes Care
Type 1 Diabetes Mellitus
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
This is a prospective, single arm, open-label, interventional, pilot study to evaluate the accuracy and precision of the continuous glucose monitoring (CGM) system of i-SENS, Inc., CareSens Air 3, in adult patients with type 1…
- Trial name
- Air3Pilot (NCT07296276)
- Testing
- CareSens Air 3 primary insertion, CareSens Air 3 secondary insertion
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- i-SENS, Inc.
Type 1 Diabetes Mellitus
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
- Trial name
- NCT01498185
- Testing
- Dapagliflozin
- Where
- 12 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.
The aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/mL formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.
- Trial name
- NCT03220425
- Testing
- Insulin detemir, NPH insulin
- Where
- 93 sites in Australia, Belgium and 8 more
- Volunteers
- 752 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics
The purpose of this study is to demonstrate the performance of the Harmony 1 Sensor in subjects age 14 - 75 years.
- Trial name
- NCT02646878
- Testing
- Harmony 1 Sensor
- Sponsor
- Medtronic MiniMed, Inc.
Diabetic Macular Edema
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema
- Trial name
- NCT00768040
- Testing
- Aliskiren
- Where
- 12 sites in United States, Denmark
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
The Role of Proper Insulin Injection Technique in the Treatment of Diabetes Mellitus
This is a prospective, post-marketing, single-arm clinical investigation on the effects of optimal insulin injection technique, in conjunction with the use of disposable Becton Dickinson (BD) Micro-Fine Plus 32G pen needles, by…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Lipohypertrophy
- Trial name
- NCT04120974
- Testing
- Optimal insulin injection
- Where
- 4 sites in Russia
- Volunteers
- 90 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week) administration to Type 1 and Type 2 diabetes patients (non-smokers)
- Trial name
- NCT00527397
- Testing
- CP-464,005
- Where
- 10 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Pfizer
Solid Tumor, Lymphoma
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in…
- Trial name
- NCT03013491
- Testing
- CX-072, ipilimumab, vemurafenib
- Where
- 31 sites in United States, Netherlands and 4 more
- Volunteers
- 196 people
- Sponsor
- CytomX Therapeutics
Type1 Diabetes Mellitus
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate bioequivalence between insulin glulisine given as 300 Units/mL test formulation and insulin glulisine 100 Units/mL reference formulation after a single subcutaneous (SC) dose.
- Trial name
- NCT02910518
- Testing
- Insulin glulisine (U300), Insulin glulisine, Insulin aspart
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Sanofi
type1diabetes, CGM
Evaluation of the Accuracy and Safety of a Continuous Glucose Monitoring System
The study is to evaluate the accuracy and safety of a real-time CGM system among adult patients with type 1 diabetes with respect to reference venous plasma sample measurements.
- Conditions
- type1diabetes, CGM, T1D
- Trial name
- NCT07745244
- Testing
- GS3 CGM
- Where
- China
- Volunteers
- 36 people
- Sponsor
- SiBionics, Co, Ltd
Diabetes Mellitus, Type 1
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, and to measure the quantity of LY2605541 in fat…
- Trial name
- NCT02109029
- Testing
- Insulin Peglispro, Human Insulin
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 1
HOME-AHCL: Home-Based Implementation of an Advanced Hybrid Closed-Loop System With Telemonitoring in Type 1 Diabetes
The goal of this prospective, single-arm observational study is to characterise a home-based setup and telemonitoring care model for an advanced hybrid closed-loop insulin pump system (Tandem Control-IQ) in adults with type 1…
- Trial name
- HOME-AHCL (NCT07492992)
- Where
- 3 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Air Liquide Healthcare Spain
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.
- Trial name
- STRIVE 2 (NCT07579702)
- Testing
- Omnipod 5 System, Omnipod 6 System
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Insulet Corporation
Diabetic Gastroparesis
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered…
- Trial name
- DIGEST (NCT01664637)
- Testing
- 10 mg TZP-102
- Where
- 35 sites in United States, Poland
- Volunteers
- 120 people
- Sponsor
- Tranzyme, Inc.
Diabetes Mellitus, Type 1
A Study in Participants With Type I Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 3 (NCT01454284)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 119 sites in United States, Australia and 18 more
- Volunteers
- 1,114 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1 Diabetes
Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study
The goal of this study is to assess the functionality of an integrated predictive low glucose suspend system designed to minimize the incidence and duration of hypoglycemia by suspending insulin delivery if hypoglycemia is…
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Insulin Pump
- Trial name
- NCT02877771
- Testing
- t:slim insulin pump with predictive low glucose suspend
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1
Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 1 diabetes.
- Trial name
- NCT00127634
- Testing
- Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine
- Where
- 61 sites in United States, Belgium and 4 more
- Volunteers
- 385 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes
This study conducted in Europe. The aim of this study is to evaluated the use of insulin detemir (Levemir®) in insufficiently controlled patients with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542463
- Testing
- insulin detemir
- Where
- Germany
- Volunteers
- 4,464 people
- Sponsor
- Novo Nordisk A/S